Medical gear maker Getinge plummets after FDA issues safety warning
** Shares in Getinge GETIb.ST drop about 8% after U.S. FDA issued a warning on the safety of two of the Swedish medical equipment maker's heart devices
** FDA advised healthcare facilities to switch from Getinge's heart devices amid safety concerns
** Getting did not immediately reply to an emailed request for comment and could not be reached for comment by phone
** Kepler Cheuvreux, via Swedbank Aktiellt, says that while nothing new has emerged, the letter from FDA could negatively impact the important U.S. market
** The broker says that demand for Getinge's products ECMO and IABP may take a hit, however, flags that the impact could be mitigated by the lack of a sales ban and alternative supplies as well as the fact that work has been ongoing to address quality issues for some time
** "This still creates uncertainty, which negatively affects the risk-return profile," Kepler adds
** Getinge's stock is the worst performing stock on the pan-European STOXX 600 index .STOXX, and, if losses hold, will see its worst day since Feb. 1
Reporting by Elsa Ohlen
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
